Literature DB >> 2549690

Feline immunodeficiency virus infection.

N C Pedersen1, J K Yamamoto, T Ishida, H Hansen.   

Abstract

Feline immunodeficiency virus (FIV) (formerly feline T-lymphotropic lentivirus or FTLV) was first isolated from a group of cats in Petaluma, California in 1986. The virus is a typical lentivirus in gross and structural morphology. It replicates preferentially but not exclusively in feline T-lymphoblastoid cells, where it causes a characteristic cytopathic effect. The major structural proteins are 10, 17 (small gag), 28 (major core), 31 (endonuclease?), 41 (transmembrane?), 52 (core precursor polyprotein), 54/62 (reverse transcriptase?), and 110/130 (major envelope) kilodaltons in size. The various proteins are antigenically distinguishable from those of other lentiviruses, although serum from EIAV-infected horses will cross-react with some FIV antigens. Kittens experimentally infected with FIV manifest a transient (several days to 2 weeks) fever and neutropenia beginning 4 to 8 weeks after inoculation. This is associated with a generalized lymphadenopathy that persists for up to 9 months. Most cats recover from this initial phase of the disease and become lifelong carriers of the virus. Complete recovery does not occur to any extent in nature or in the laboratory setting. One experimentally infected cat died from a myeloproliferative disorder several months after infection. The terminal AIDS-like phase of the illness has been seen mainly in naturally infected cats. It appears a year or more following the initial infection in an unknown proportion of infected animals. FIV has been identified in cats from all parts of the world. It is most prevalent in high density populations of free roaming cats (feral and pet), and is very uncommon in closed purebred catteries. Male cats are twice as likely to become infected as females. Older male cats adopted as feral or stray animals are at the highest risk of infection, therefore. The infection rate among freely roaming cats rises throughout life, and reaches levels ranging from less than 1% to 12% or more depending on the area. Clinically affected cats tend to be 5 years or older at the time of hospitalization. Experimental and seroepidemiologic studies suggest that FIV is transmitted mainly by bites. Intimate, non-traumatic contact (mutual grooming, shared use of food, water and litter pans) is inefficient in transmitting the infection. In utero and venereal transmission could not be demonstrated in laboratory settings. There is no statistical linkage between FIV and feline leukemia virus (FeLV) infections in nature. The FeLV infection rate in FIV-infected animals is the same as it is for non-FIV-infected cats.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549690     DOI: 10.1016/0165-2427(89)90134-7

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  73 in total

1.  Naturally acquired feline immunodeficiency virus (FIV) infection in cats from western Canada: Prevalence, disease associations, and survival analysis.

Authors:  Madhu Ravi; Gary A Wobeser; Susan M Taylor; Marion L Jackson
Journal:  Can Vet J       Date:  2010-03       Impact factor: 1.008

2.  Comparison of two host cell range variants of feline immunodeficiency virus.

Authors:  T R Phillips; R L Talbott; C Lamont; S Muir; K Lovelace; J H Elder
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Detection of feline immunodeficiency virus in semen from seropositive domestic cats (Felis catus).

Authors:  H L Jordan; J Howard; W A Tompkins; S Kennedy-Stoskopf
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  In vivo lymphocyte tropism of feline immunodeficiency virus.

Authors:  R V English; C M Johnson; D H Gebhard; M B Tompkins
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

Review 6.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Processing of the glycoprotein of feline immunodeficiency virus: effect of inhibitors of glycosylation.

Authors:  E B Stephens; E Monck; K Reppas; E J Butfiloski
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  Localization of the viral antigen of feline immunodeficiency virus in the lymph nodes of cats at the early stage of infection.

Authors:  T Toyosaki; T Miyazawa; T Furuya; K Tomonaga; Y S Shin; M Okita; Y Kawaguchi; C Kai; S Mori; T Mikami
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  Association of plasma viral RNA load with prognosis in cats naturally infected with feline immunodeficiency virus.

Authors:  Yuko Goto; Yoshiaki Nishimura; Kenji Baba; Takuya Mizuno; Yasuyuki Endo; Kenichi Masuda; Koichi Ohno; Hajime Tsujimoto
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro.

Authors:  Jia Ma; Suzanne Kennedy-Stoskopf; Jesse M Jaynes; Linda M Thurmond; Wayne A Tompkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.